Clinical Trials · NCT01514149
Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- ConjuChem
- Enrollment
- 73
- Start date
- Sep 2011
- Locations
- 22 sites, United States, Canada
- Primary endpoint
- Glycosylated Hemoglobin Change From Baseline (CFB) to Week 18